The Response Of Hekma Centers Team:
The team replied to his message, and congratulated him for overcoming herpes virus after taking one supplement package:
Dear Al,
Hope everything is well with you. Thank you very much for your kind and warm words, every single word means a lot for us. We are more than glad to know that you are cured, this is what we always striving to do.
We know that it is hard to believe in a cure for certain disease that it is known worldwide there is no cure for it, and it becomes harder when the surrounding people do not encourage you but fortunately you took the chance, and thank God, you are cured.
Your faith and commitment was an important part of the healing process, congratulations. Thank you so much for the update, and thank you for giving us the permission to publish your testimony. For sure we will not reveal the name, we just keep the first two letters of the name for comparison purpose, and we hide all the rest details.
Can you please send me the test result that shows you are positive for HSV before starting with the treatment ?
Mr. Al did not hesitate to send us his previous medical reports:
We congratulate Mr. Al for overcoming HSV. And thank him for his sincere and genuine words that every patient can relate to. Before and after overcoming the disease.
How To Find Genital Herpes Clinical Trials In The Blink Of An Eye With The Help Of Donotpay
There is no easier way of looking for HSV 2 clinical trials than by using DoNotPay. The worlds first robot lawyer can find one for you in a heartbeat. You will only need to do the following:
And youre done! Researchers should contact you within several days once youre done completing the steps. DoNotPay keeps no fees, so you can save the entire compensation for yourself. Get in touch with as many studies as you like. Bookmarking is another great feature that we offer for when you want to save a study that isnt enrolling yet.
‘i Hope That This Study Changes The Dialogue Around Herpes Research And Opens Up The Idea That We Can Start Thinking About Cure Rather Than Just Control Of The Virus’
â Dr. Keith Jerome, Fred Hutchinson Cancer Research Center
Whereas most research on herpes has focused on suppressing the recurrence of painful symptoms, the Fred Hutch gene therapy work addresses the root cause of reactivation: the presence of latent virus in infected nerve cells.
âI hope that this study changes the dialogue around herpes research and opens up the idea that we can start thinking about cure, rather than just control of the virus,â Jerome said.
It will still take a long time before these experiments lead to the first human trials of gene therapy to cure herpes. Jerome estimates that will be at least three years away.
Herpes simplex viruses afflict billions of human beings around the globe. According to the World Health Organization, two-thirds of the world population under the age of 50 carry herpes simplex virus type 1, or HSV-1, which primarily causes cold sores, while 491 million people aged 15-49 are infected with closely related HSV-2, which is the cause of sexually transmitted genital herpes.
You May Like: Foods That Help Herpes Outbreaks
A Cure For Herpes There Is Progress To Report
It takes a persistent scientist to stop a persistent virus.
A decade ago, Fred Hutchinson Cancer Research Center virologist Dr. Keith Jerome began exploring the idea that lifelong infections with herpes viruses might be cured by using the DNA-cutting tools of gene therapy.
Initial research showed these techniques could knock out small quantities of latent virus, and the work of improving the results fell to Jeromeâs senior staff scientist, Dr. Martine Aubert. Five years ago, the team reported they had damaged the genes of 2%-4% of herpes virus in infected mice. Aubertâs work was an important proof of principle, but far short of a cure.
Nevertheless, she persisted.
On Aug. 18, the team led by Jerome and Aubert published a paper in Nature Communications showing that, through a series of incremental improvements on their original method, they had destroyed up to 95% of herpes virus lurking in certain nerve clusters of mice.
âThis is the first time that anybody has been able to go in and actually eliminate most of herpes in a body,â said Jerome, who is also spearheading research at Fred Hutch and the University of Washington on COVID-19. âIt is a completely different approach to herpes therapy than anybodyâs ever had before.â
It Will Still Take A Long Time Before These Experiments Lead To The First Human Trials Of Gene Therapy To Cure Herpes Jerome Estimates That Will Be At Least Three Years Away
The team attained its first promising results years ago using a single type of meganuclease that proved effective in cutting the herpes virus DNA, but the results were short-lived. The virus could rely on the infected cellsâ own DNA-repair programs â which donât distinguish between viral genes from their own â to fix the break most of the time.
But over time, the researchers found that they could eliminate up to 90% of the latent virus by using a mix of two or three different meganucleases. It is simply harder to repair two breaks than one. With more tinkering, the results continued to improve.
Don’t Miss: How To Stop Herpes Outbreak
What Are Clinical Trials For Hsv 2
Herpes simplex virus is the cause of herpes. There are two types of HSV virus:
- HSV 1cause of cold sores around the mouth
- HSV 2cause of genital herpes
According to WHO, around 417 million people across the globe have an HSV 2 infection, while 140 million have an HSV 1 infection. HSV 2 can cause infections in newborns and also attack people with weak immune systems. A person who has this virus also has a higher chance of getting an HIV infection and spreading it to another person. Due to these great numbers and alarming factors, researchers are looking for a vaccine that could help stop the spread of the virus. This is where clinical trials come in.
HSV 2 clinical trials are medical observations and experiments conducted on volunteers in order to find the best cure for herpes. They are as common as any other clinical trial, and you need to check certain criteria to be able to volunteer in them. The goal of HSV 2 clinical trials is to find a better treatment for herpes and help people who live with it lead better lives. You would be included in experiments and observations specifically made for finding a cure for HSV 2. These can differ depending on the way the facility and researchers find it best to test the treatments.
Assuring Safety Before Human Trials Can Begin
The researchers are performing additional preclinical studies of the therapy in guinea pigs, which, unlike mice, have naturally recurring outbreaks from latent herpes infections. As with the mice, the initial focus of this research is in HSV-1, which is primarily associated with cold sores. However, Fred Hutch researcher Dr. Anna Wald points out that recent studies, including one she published with colleagues at the University of Washington, are hinting at a shift.
HSV-1 is becoming â particularly in first infections for adults under 30 â the leading cause of genital herpes, the more feared condition that has been traditionally associated with HSV-2. Regardless, if the experimental therapy works for HSV-1, the researchers are confident it can be relatively easily adapted to target HSV-2.
Wald, who also heads the Division of Allergy and Infectious Diseases at UW, has been researching vaccines to prevent or treat HSV infection since 1991. She said that Jerome and Aubertâs work is a paradigm shift in the field, because the assumption has been that once a person is infected with a herpesvirus â and there are eight members of that family â it is impossible to get rid of that particular strain.
âIt is a completely novel approach, in which you can take a member of the herpesvirus group and eradicate it from the host. As a proof of principle, the fact that it could be done on even one of them is kind of mind-boggling,â she said.
You May Like: Dating Someone With Herpes 2
One Herpes Package Is All Mr Al From Oman Needed To Overcome Hsv
On 4.2.2021, Mr. Al sent the team at Hekma Center a message, informing them that he completely overcame herpes virus, and he confirmed it after taking a PCR blood test.
Dear specialists from Hekma Center, this month I did the PCR blood test for Hsv 1& 2 and it came Not detected. I was desperate when I contacted you but I was very determined, even though my friends told me not to believe in alternative medicine. I didnt know if I was making the right thing, I just believed it because I needed to believe.
Now I am writing to celebrate with you, now I am writing to show my gratitude and respect for your knowledge and experience. I respected all your indications and I must say it was for the first time in my life when I followed a diet and plan thoroughly. Thats because it was for the first time in my life when I was frightened for my life and for my future. I am still young, I see myself still young and I still wanted to love and be loved, just like any other human being. I felt guilty and I knew that I did mistakes. But eventually, I saw this passage Ive been through as a chance to correct myself- this gave me strength.
When I received the package from you and I saw it comes from Jerusalem, I cried because I am a believer and I saw it as from Holly place. It gave me strength and hope, because when it comes for believing, I am still the child my mother and grandmother took to Church.
One Herpes Package Is All Mr Al Needed To Overcome Hsv
** Please note : We do not reveal the full name of the patient, we just keep the first two letters of the name for comparison purpose, and we hide all the rest details. Photos are for clarification purpose only and are not the real photos of the patients.
Dear specialists from Hekma Center, This month I did the PCR blood test for Hsv 1& 2 and it came Not detected
This is part of Mr. Als message to the specialized team at Hekma Center. Revealing that he overcame herpes virus entirely.Read his story from the start.
You May Like: I Was Diagnosed With Herpes And Never Had An Outbreak
Herpes Vaccine Clinical Trials
There are currently both preventive and therapeutic vaccines under development. While the primary focus is on HSV-2, the primary cause of genital infection, HSV-2 vaccines may also have benefits in preventing or treating HSV-1 infection. In addition to work being done in the preclinical stage, there are several vaccines in clinical trials.
More information on recent and ongoing clinical trials can be found at:
Articles Ongenital Herpes Treatment
The process of introducing a new treatment to the public can be a long one. Before the FDA approves a drug, it must go through rigorous clinical trials, which are divided into three phases. In phase I, researchers try to find out if the drug is safe for people to take. If the drug is deemed safe, it may go on to phase II, when researchers aim to determine if the drug works as it should. They also collect more safety data. In phase III trials, they expand their research to include more patients in more places.
To conduct a clinical trial, scientists need people to participate voluntarily. Clinical trials often involve thousands of patients who volunteer to take the experimental drug. The FDA and an independent review board carefully monitor every aspect of the trial. There are rules the researchers must follow to ensure that their work is scientifically correct and ethically sound. The study volunteers have clearly defined rights, such as the right to drop out of the trial at any time.
Also Check: Does Valacyclovir Stop The Spread Of Herpes
Phase Iia Efficacy Endpoints
The primary efficacy endpoint was the effect of early treatment at the prodromal stage of herpes lesions triggered by a dental procedure. This was based on comparing the rate of progression from the prodromal to the vesicle stage in treatment versus control subjects. A treatment success was the blocking or diminishing of prodromal lesions progressing to the vesicle stage. There were two secondary endpoints. The first was the time to healing of lesions that were not blocked from progressing to the vesicle stage in treatment versus control subjects. The other secondary endpoint was the rate of viral shedding between treatment and control subjects, based on viral swabs of lesions taken at Visits 25. Separate from efficacy, any pain subjects experienced from their herpes lesions was assessed over all days lesions were present, using an 11-point Likert pain scoring scale .
Phase Iia Clinical Trial Objective
The objective of the randomized, double-blind, placebo-controlled Phase IIa clinical trial was to determine the safety and efficacy of sublingually administered low-dose BTL-TML on the recurrence of orofacial mucocutaneous HSV infections within seven days of each trial subject’s dental procedures. Trial subjects were persons with a history of recurrent HSV that were to undergo routine dental procedures, either preventive or interventional .
Read Also: Why Do I Have Frequent Herpes Outbreaks
Phase Iib Clinical Trial Objective
Trial subjects for the randomized, double-blind, placebo-controlled Phase IIb clinical trial were persons with a history of recurrent HSV that were to undergo experimental UV irradiation of the lips. The objective was to determine the efficacy of sublingually administered low-dose BTL-TML in blocking the progression of cold sore lesions beyond the prodromal stage.
Clinical Trials: Key To Genital Herpes Research
Although these new genital herpes treatments are just on the horizon, it may be years before any are available to consumers.
The process of introducing a new treatment to the public can be a long one. Before the FDA approves a drug, it must go through rigorous clinical trials, which are divided into three phases. In phase I, researchers try to find out if the drug is safe for people to take. If the drug is deemed safe, it may go on to phase II, when researchers aim to determine if the drug works as it should. They also collect more safety data. In phase III trials, they expand their research to include more patients in more places.
To conduct a clinical trial, scientists need people to participate voluntarily. Clinical trials often involve thousands of patients who volunteer to take the experimental drug. The FDA and an independent review board carefully monitor every aspect of the trial. There are rules the researchers must follow to ensure that their work is scientifically correct and ethically sound. Study volunteers have clearly defined rights, such as the right to drop out of the trial at any time.
Recommended Reading: What Kills Herpes On Surfaces
Description Of Study Medication
Beech Tree Labs low-dose TML formulation, hereafter abbreviated BTL-TML, was composed of 4 ug/ml of TML in physiological saline . Clinical trial supplies were provided in dropper bottles for sublingual administration. Each sublingual dose thus contained 0.2 ug BTL-TML. The placebo was physiological saline in matching dropper bottles. Dosing was achieved by each subject self-administering a drop of BTL-TML sublingually, maintaining sublingual contact for 30 seconds, and then swallowing their oral saliva. The specific dosing regimen was as follows: On the first day of cold sore symptoms, subjects self-administered one sublingual drop of BTL-TML every 15minutes for the first hour, followed by one drop sublingually every hour for eight hours or until bedtime on the second and third days of symptoms, subjects took one drop sublingually every four hours and on days 47 after experiencing symptoms, subjects took one sublingual drop every 12hours. All clinical trial subjects had to demonstrate their ability to self-administer the sublingual drops as one of the clinical trial inclusion criteria. Assuming a given subject followed the dosing regimen to completion, it was estimated that the cumulative amount of BTL-TML would be about 7 ug. This compares to 50 ug of TML in a typical 0.5ml injection of influenza vaccine.
Phenotypic And Functionally Differential Hsv
Figure 1 Schematic of Prime-Pull-Keep Therapeutic Vaccine . The PPK vaccine is designed to boost Neutralizing IgG/IgA antibodies and boost the number and function of antiviral CD4+ and CD8+ TRM cells within the cervico genital muco-cutaneous and dorsal root ganglia tissues. The PPK vaccine is expected to help STOP the virus reactivation from latently infected DRG, virus shedding and virus replication in CGMC, thus curing or reducing recurrent genital herpes disease. *, represent virus.
Don’t Miss: New Treatment For Genital Herpes
Positive Impact For Mild Side Effects
Researchers looked at patient biopsies before and after injections of the RP2 virus and found positive changes in the area immediately surrounding the tumour.
Injections led to more immune cells in the area and switched on genes linked to the immune response cracking down on cancer cells, the authors explained.
Researchers found that most side effects of RP2 were mild, the most common being fever, chills, and fatigue.
The team now hopes to continue exploring the potential of this strategy in a larger number of patients.
Viruses are one of humanitys oldest enemies, as we have all seen over the pandemic. But our new research suggests we can exploit some of the features that make them challenging adversaries to infect and kill cancer cells, said Professor Kristian Helin, Chief Executive of The Institute of Cancer Research, London.
Its a small study but the initial findings are promising. I very much hope that as this research expands we see patients continue to benefit.